ImmunityBio (IBRX) Gains from Sales and Divestitures (2015 - 2021)
ImmunityBio (IBRX) reported Gains from Sales and Divestitures of $336084.0 for Q2 2021, down 39.88% year-over-year from $558976.0 in Q2 2020, and up 42.57% quarter-over-quarter from $235725.0 in Q1 2021.
ImmunityBio (IBRX) Gains from Sales and Divestitures (2015 - 2021) Analysis & Trends
ImmunityBio (IBRX) has 7 years of Gains from Sales and Divestitures data on file, last reported at $336084.0 in Q2 2021.
- Gains from Sales and Divestitures for Q2 2021 came in at $336084.0, down 39.88% year-over-year; the trailing twelve-month figure through Jun 2021 was $336084.0 (down 39.88% YoY), and the FY2020 annual result was $648336.0, up 64.11% from the prior year.
- Gains from Sales and Divestitures improved to $336084.0 in Q2 2021 per IBRX's latest filing, from $235725.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $648336.0 in Q4 2020 and troughed at $6625.0 in Q1 2017.
- A 5-year average of $234234.9 and a median of $172330.0 in 2018 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2017 and 2018: Gains from Sales and Divestitures sank 93.04% in 2017, then jumped 959.62% in 2018.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $244209.0 in 2017, then decreased by 29.43% to $172330.0 in 2018, then soared by 129.24% to $395051.0 in 2019, then surged by 64.11% to $648336.0 in 2020, then plunged by 48.16% to $336084.0 in 2021.
- Business Quant data shows IBRX's Gains from Sales and Divestitures at $336084.0 in Q2 2021, $235725.0 in Q1 2021, and $648336.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 336,084.00 |
| Jun 30, 2021 | 336,084.00 |
| Mar 31, 2021 | 235,725.00 |
| Mar 31, 2021 | 235,725.00 |
| Dec 31, 2020 | 648,336.00 |
| Dec 31, 2020 | 648,336.00 |
| Sep 30, 2020 | 642,236.00 |
| Sep 30, 2020 | 642,236.00 |
| Jun 30, 2020 | 558,976.00 |
| Jun 30, 2020 | 558,976.00 |
| Mar 31, 2020 | 63,750.00 |
| Mar 31, 2020 | 63,750.00 |
| Dec 31, 2019 | 395,051.00 |
| Dec 31, 2019 | 395,051.00 |
| Sep 30, 2019 | 247,601.00 |
| Sep 30, 2019 | 247,601.00 |
| Jun 30, 2019 | 157,291.00 |
| Jun 30, 2019 | 157,291.00 |
| Mar 31, 2019 | 49,775.00 |
| Mar 31, 2019 | 49,775.00 |